Many patients with psoriasis remain undertreated
The treatment journey for patients with psoriasis differs for every patient, and may include topicals, phototherapy, systemic orals and biologics. Despite the availability of these various treatment options, many patients still struggle to control their disease because they are frequently either undertreated or even untreated. Additionally, they may feel dissatisfied with their current treatment regimens or find it difficult to reach their treatment goals. Therefore, a significant need exists for additional effective and well-tolerated therapies.
A key pathway for psoriasis & immune-mediated diseases
At Bristol Myers Squibb, we are exploring selective inhibition of TYK2 (tyrosine kinase 2). TYK2 is a naturally occurring enzyme in the body, known as an intracellular signaling kinase, that has been shown to play a key role in several immune-mediated diseases, including psoriasis as well as psoriatic arthritis and IBD. TYK2 facilitates signaling of IL-23, IL-12 and Type I IFN, which are inflammatory cytokines overexpressed in psoriasis and other diseases.
By selectively inhibiting TYK2, we are targeting underlying disease pathways that are critical in the cycle of chronic inflammation contributing to these conditions.
Advancing patient care through scientific innovation
With a history of helping patients prevail over serious disease, Bristol Myers Squibb is focused on developing solutions for the psoriasis community with the hope of transforming care. Our pioneering exploration of pathways implicated in psoriasis and other immune-mediated diseases is leading to the potential for new innovations. Additionally, we are working closely with the community to understand how we can offer support that goes beyond the medicine.
As we move forward, our commitment is to help free patients from the burden of immune-mediated diseases like psoriasis, so that we can change lives for the better.